Target & Activity
| Target | Activity | Value |
|---|---|---|
| HIV-1 |
Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| CCRF-CEM | EC50 | 100 nM | Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay | [PMID: 17576848] |
| CCRF-CEM | EC50 | 177 nM | Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay | [PMID: 17576848] |
| CCRF-CEM | EC50 | 199 nM | Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay | [PMID: 17576848] |
| CCRF-CEM | EC50 | 281 nM | Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay | [PMID: 17576848] |
| CEM-SS | ED50 | 0.03 μM | Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay | [PMID: 15217281] |
| CEM-SS | IC50 | 2 nM | Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as reverse transcriptase activity after 5 days by MTT assay | [PMID: 17950955] |
| HEK293 | EC50 | 5.8 nM | Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay | [PMID: 17638694] |
| HeLa | EC50 | > 1 μM | Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay | [PMID: 19805571] |
| HeLa | EC50 | > 1 μM | Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay | [PMID: 17646410] |
| HeLa | EC50 | > 1 μM | Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay | [PMID: 17646410] |
| HeLa | EC50 | 0.013 μM | Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay | [PMID: 19805571] |
| HeLa | EC50 | 0.016 μM | Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay | [PMID: 19805571] |
| HeLa | EC50 | 0.038 μM | Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay | [PMID: 19805571] |
| HepG2 | CC50 | 7.4 μM | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay | 10.1039/C1MD00147G |
| LLC-PK1 | IC50 | 2.3 μM | Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay | [PMID: 12699389] |
| LLC-PK1 | IC50 | 3.4 μM | Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay | [PMID: 12699389] |
| MOLT-4 | EC50 | 0.029 μM | Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay | [PMID: 18316521] |
| MT2 | EC50 | 0.023 μM | Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay | [PMID: 18955518] |
18 records · Scroll to view more